{"id":"W4387811091","doi":"10.1016/j.annonc.2023.09.2185","title":"1046P Phase I/II open-label study on an anti-GPC3 T cell engager, SAR444200, in patients with advanced solid tumors: Preliminary dose escalation results","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval","funders":"PharmaMar; CRIS Cancer Foundation; Sociedad Española de Oncología Médica; European Society for Medical Oncology; American Society of Clinical Oncology; BeiGene; Sanofi","keywords":"Medicine; Cytokine release syndrome; Glypican 3; Pharmacokinetics; Oncology; Adverse effect; T cell; Internal medicine; Biomarker; Gastroenterology; Cancer; Cancer research; Immunotherapy; Immunology; Chimeric antigen receptor; Immune system","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001288636,0.001986405,0.001652132,0.0005343976,0.0004637495,0.001207683,0.0007809642,0.001427313,0.004719653],"category_scores_gemma":[0.0007085776,0.0005270284,0.001585419,0.0004578328,0.0009122955,0.0007958289,0.0003302009,0.004790866,0.00129002],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009643073,"about_ca_system_score_gemma":0.001423318,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001824727,"about_ca_topic_score_gemma":0.00402996,"domain_scores_codex":[0.9996437,0.0001606436,0.0000106465,0.00004855639,0.00004162372,0.00009489958],"domain_scores_gemma":[0.9994973,0.00009915828,0.00006494356,0.00004620479,0.0000335752,0.000258818],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4164718,0.1208453,0.00693622,0.001271936,0.002546096,0.0004863529,0.0007048812,0.01471408,0.1136861,0.001158708,0.0234291,0.2977494],"study_design_scores_gemma":[0.4103569,0.5456467,0.01691714,0.00006977668,0.0008170781,0.0004445254,0.0001577364,0.00521435,0.009709037,0.0009903142,0.009608478,0.00006793893],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9834732,0.002100562,0.001735749,0.001402942,0.0002236756,0.00221454,0.003127862,0.0003901436,0.005331194],"genre_scores_gemma":[0.97162,0.002636281,0.00465025,0.001950656,0.0001976996,0.002340533,0.006460537,0.0001677058,0.009976289],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004719653,"threshold_uncertainty_score":0.01578879,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1514363011465199,"score_gpt":0.479152712210533,"score_spread":0.3277164110640131,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}